User:Mr. Ibrahem/Tezacaftor/ivacaftor
| Combination of | |
|---|---|
| Tezacaftor | CFTR corrector |
| Ivacaftor | CFTR potentiator |
| Clinical data | |
| Trade names | Symkevi, Symdeko |
| AHFS/Drugs.com | Monograph |
| Pregnancy category |
|
Tezacaftor/ivacaftor, sold under the brand name Symdeko, is a combination medication of tezacaftor and ivacaftor used to treat cystic fibrosis.[1] It is only used in people with specific mutations.[1] It is taken by mouth.[1]
Common side effects include nausea, headache, diarrhea, and dizziness.[1] Other side effects may include liver problems and cataracts.[1][3] In those with significant liver problems a lower dose may be required.[3] Tezacaftor increases the number of CFTR while ivacaftor increases the ability of CFTR.[2]
The combination was approved for medical use in the United States and Europe in 2018.[3][2] In the United States it costs about 304,000 USD per year as of 2021.[4] It became available in the United Kingdom in 2020 at a cost of about £82,000 per year.[5]
References
change- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Tezacaftor and Ivacaftor Monograph for Professionals". Drugs.com. Archived from the original on 27 February 2021. Retrieved 8 October 2021.
- ↑ 2.0 2.1 2.2 "Symkevi". Archived from the original on 8 January 2021. Retrieved 8 October 2021.
- ↑ 3.0 3.1 3.2 "SYMDEKO™ (tezacaftor/ivacaftor) tablets; (ivacaftor) tablets, for oral use" (PDF). Archived (PDF) from the original on 9 June 2021. Retrieved 8 October 2021.
- ↑ "Symdeko Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 11 November 2020. Retrieved 8 October 2021.
- ↑ "Tezacaftor + ivacaftor". SPS - Specialist Pharmacy Service. 29 December 2015. Archived from the original on 26 February 2021. Retrieved 8 October 2021.